Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: ImmuCell operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industries. Key products include First Defense® and Wipe Out® Dairy Wipes. The company is heavily dependent on the successful development of new products, specifically a partnership with Pfizer for the product Mast Out®.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Total Revenues | $1,034,957 | $3,614,975 |
| Net Income | $109,437 | $448,153 |
| Net Income Per Share (Diluted) | $0.04 | $0.15 |
| Operating Cash Flow | N/A | $499,343 |
| Cash and Cash Equivalents | $1,303,079 | $1,303,079 |
| Short-term Investments | $3,585,658 | $3,585,658 |
| Total Assets | $9,748,386 | $9,748,386 |
| Total Liabilities | $1,455,833 | $1,455,833 |
| Shareholders' Equity | $8,292,553 | $8,292,553 |
| Debt | $0 (No outstanding bank debt) | $0 |
Gross Margins: Gross margin as a percentage of product sales was 66% for the three months ended September 30, 2005, and 62% for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 22% ($189,000) for the three months and 31% ($862,000) for the nine months compared to the same periods in 2004. This growth was driven by product sales increases and significant revenue from the sale of technology rights ($240,000 in Q3; $486,000 in YTD) related to the Pfizer agreement.
- Profitability: The company reported a net income of $109,437 for the quarter, a significant improvement from a net loss of $5,074 in the same period in 2004. For the nine months, net income rose to $448,153 from $109,062 in 2004.
- Expense Trends: Research and development (R&D) expenses increased 31% in the quarter and 26% year-to-date, largely due to amortization of the intangible asset from the Nutrition 21 license buyout and costs associated with supplying clinical material to Pfizer. General and administrative expenses also rose, primarily due to personnel and consulting costs.
- Liquidity: Net working capital increased 13% to $5,643,000. Cash and short-term investments combined increased 10% to $4,889,000 compared to December 31, 2004.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management believes it has sufficient capital resources to meet working capital requirements for at least the next twelve months. The company is focused on the development of Mast Out® in partnership with Pfizer, which includes contingent milestone payments (up to $750,000 potential in 2006) and future royalties. Product sales of First Defense® and Wipe Out® are expected to remain seasonal, with sales positively affected by higher milk prices but challenged by economic pressures on small dairy producers.
Risks and Contingencies:
- Regulatory Risk: Continued sales of First Defense® depend on USDA approval of the Reference Standard. Wipe Out® Dairy Wipes are currently sold under a compliance policy guide but may face future FDA New Animal Drug Application (NADA) requirements that could impact profitability.
- Market Risk: The company is heavily dependent on the U.S. dairy industry, which faces economic pressures and a decline in the number of small producers. There is also a risk of bovine disease epidemics (e.g., BSE) affecting the industry.
- Operational Risk: The company relies on a single manufacturing facility in Portland, Maine, and key employees with little redundancy. Disruption at this facility could halt production.
- Concentration Risk: A significant portion of product sales (16% in Q3 2005) comes from a single customer, Walco International, Inc.
Investor Verification Checklist
- Pfizer Agreement Status: Verify the progress of clinical trials for Mast Out® and the likelihood of achieving the $750,000 milestone payments scheduled for 2006.
- Customer Concentration: Assess the stability of the relationship with Walco International, Inc., which accounts for a significant portion of sales and receivables.
- Regulatory Compliance: Monitor USDA and FDA regulatory environments regarding First Defense® and Wipe Out® Dairy Wipes to ensure no new compliance costs or restrictions arise.
- Stock-Based Compensation: Note that the company currently uses the intrinsic value method (APB 25) for stock-based compensation. Pro forma net income would be lower ($432,769 for the nine months) if FAS 123R fair-value accounting were applied.
- Deferred Revenue: Review the recognition schedule for the $1,500,000 Pfizer upfront payment, which is being amortized through December 31, 2007.